Ascendis Pharma A/S
ASND
228.41
+2.36
+1.04%
Ascendis Pharma A/S
US · ASND
#1127 by market cap
Listed 2015
228.41
+2.36
+1.04%
Live - 5344 symbols - heartbeat 99s ago
· 2026-10-07 23:39
After-hours
228.41
0.00%
Overnight
229.84
+0.63%
- Market cap
- 15.03B
- P/E (TTM)i
- 18.23
- P/Bi
- 9.35
- EPSi
- -4.21
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on ASND?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.1 percentage points.
Institutional ownership
- Held by institutions
- 103.59% +0.13pp
- Institutions
- 371 +5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund68.04%
VC/PE Fund18.25%
Hedge Fund13.02%
Public Company2.22%
Private Company0.94%
Government Pension Fund0.58%
Sovereign Wealth Fund0.33%
Top holders as of 2026-06-30
RA Capital Management, L.P.
15.66% · 10.28M sh
T. Rowe Price Group, Inc.
11.99% · 7.88M sh
Avoro Capital Advisors LLC
7.78% · 5.11M sh
Westfield Capital Management Company, L.P.
7.31% · 4.80M sh
Janus Henderson Group plc
5.56% · 3.65M sh
FMR
5.40% · 3.55M sh
Capital Research
4.49% · 2.95M sh
Artisan Partners Limited Partnership
4.01% · 2.63M sh
BlackRock
3.37% · 2.21M sh
MFS Investment Management
2.86% · 1.88M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 6 buys · 4 sells
| Name | Role | Stake |
|---|---|---|
| Scott Smith | CFO, Executive VP & Member of Executive Board | 0.01% |
| Lars Holtug | Independent Director | 0.01% |
| Jean-Jacques Bienaime | Non-Executive Director | 0.00% |
| Albert Cha | Independent Chairperson | -- |
| Jan Mikkelsen | President, CEO, Member of Executive Board & Executive Director | -- |
| Michael Jensen | Executive VP, Chief Legal Officer & Member of the Executive Board | -- |
| Flemming Jensen | Executive Vice President of Product Supply & Quality - Endocrinology Rare Diseases | -- |
| Pedersen Anni Lotte Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board | -- |
| Mads Bodenhoff | Senior VP of Finance & Principal Accounting Officer | -- |
| William Fairey | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-07 | Mads Bodenhoff | Senior VP of Finance & Principal Accounting Officer | Derivative Exercise and Sale | -3,000 | $110.00–270.19 |
| 2026-09-01 | Lars Holtug | Independent Director | Open Market Disposition | -236 | $264.13 |
| 2026-08-13 | Jean-Jacques Bienaime | Non-Executive Director | Open Market Acquisition | +2,000 | $245.85–246.91 |
| 2026-06-01 | Scott Smith | CFO, Executive VP & Member of Executive Board | Open Market Acquisition | +100 | $219.00 |
| 2026-05-28 | Jean-Jacques Bienaime | Non-Executive Director | Open Market Acquisition | +500 | $222.30–223.76 |
| 2026-05-28 | Scott Smith | CFO, Executive VP & Member of Executive Board | Open Market Acquisition | +250 | $223.32 |
| 2026-05-25 | Jean-Jacques Bienaime | Non-Executive Director | Open Market Acquisition | +400 | $236.24–239.37 |
| 2026-05-10 | Flemming Jensen | Executive Vice President of Product Supply & Quality - Endocrinology Rare Diseases | Open Market Disposition | -19,460 | $238.49 |
| 2026-04-13 | Jean-Jacques Bienaime | Non-Executive Director | Derivative Sale to Issuer | -9,160 | -- |
| 2026-04-13 | Jean-Jacques Bienaime | Non-Executive Director | Other Derivative Acquisition | +9,160 | $249.84 |
| 2026-03-22 | Jean-Jacques Bienaime | Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Albert Cha | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Jan Mikkelsen | President, CEO, Member of Executive Board & Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Michael Jensen | Executive VP, Chief Legal Officer & Member of the Executive Board | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Flemming Jensen | Executive Vice President of Product Supply & Quality - Endocrinology Rare Diseases | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Pedersen Anni Lotte Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Mads Bodenhoff | Senior VP of Finance & Principal Accounting Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | William Fairey | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Lisa Morrison | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Scott Smith | CFO, Executive VP & Member of Executive Board | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 23:39:45 · For reference only, not investment advice and not tailored to your situation.